Clinical Track

Myocardial Ischemia and Reperfusion Leads to Transient CD8 Immune Deficiency and Accelerated Immunosenesence in CMV-Seropositive Patients


Rationale: There is mounting evidence of a higher incidence of coronary heart disease in cytomegalovirus-seropositive individuals.

Objective: The aim of this study was to investigate whether acute myocardial infarction triggers an inflammatory T-cell response that might lead to accelerated immunosenescence in cytomegalovirus-seropositive patients.

Methods and Results: Thirty-four patients with acute myocardial infarction undergoing primary percutaneous coronary intervention were longitudinally studied within 3 months after reperfusion (Cohort A). In addition, 54 patients with acute myocardial infarction and chronic myocardial infarction were analyzed in a cross-sectional study (Cohort B). Cytomegalovirus-seropositive patients demonstrated a greater fall in the concentration of terminally differentiated CD8 effector memory T cells (TEMRA) in peripheral blood during the first 30 minutes of reperfusion compared with cytomegalovirus-seronegative patients (−192 versus −63 cells/μL; P=0.008), correlating with the expression of programmed cell death-1 before primary percutaneous coronary intervention (r=0.8; P=0.0002). A significant proportion of TEMRA cells remained depleted for ≥3 months in cytomegalovirus-seropositive patients. Using high-throughput 13-parameter flow cytometry and human leukocyte antigen class I cytomegalovirus-specific dextramers, we confirmed an acute and persistent depletion of terminally differentiated TEMRA and cytomegalovirus-specific CD8+ cells in cytomegalovirus-seropositive patients. Long-term reconstitution of the TEMRA pool in chronic cytomegalovirus-seropositive postmyocardial infarction patients was associated with signs of terminal differentiation including an increase in killer cell lectin-like receptor subfamily G member 1 and shorter telomere length in CD8+ T cells (2225 versus 3397 bp; P<0.001).

Conclusions: Myocardial ischemia and reperfusion in cytomegalovirus-seropositive patients undergoing primary percutaneous coronary intervention leads to acute loss of antigen-specific, terminally differentiated CD8 T cells, possibly through programmed cell death-1–dependent programmed cell death. Our results suggest that acute myocardial infarction and reperfusion accelerate immunosenescence in cytomegalovirus-seropositive patients. (Circ Res. 2015;116:87-98. DOI: 10.1161/CIRCRESAHA.116.304393.)

Key Words: aging • cytotoxic T-lymphocytes • human cytomegalovirus • myocardial infarction • programmed cell death 1 • reperfusion • telomere

*These authors contributed equally to this article.

Original received May 16, 2014; revision received October 29, 2014; accepted November 10, 2014. In October, 2014, the average time from submission to first decision for all original research papers submitted to Circulation Research was 16 days.

From the Institute of Genetic Medicine (J.H., E.V.S., S.E.B., S.M., B.K., I.S.), Institute of Aging and Health (C.M.-R., T.v.Z.), and Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom (A.B., M.E., R.D., I.S.), Department of Cardiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom (A.B., M.E., R.D., I.S.); Flow Cytometry Core Facility, International Center for Life, Newcastle upon Tyne, United Kingdom (I.D.); Department of Immunology, Institute of Medical Microbiology and Hygiene, Freiburg University, Germany (H.P.); CLIP—Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic (K.F.); University Hospital Motol, Prague, Czech Republic (K.F.); Institute of Cardiovascular Sciences, The University of Manchester, United Kingdom (B.K.); and Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom (S.M., S.T.).

The online-only Data Supplement is available with this article at http://circres.ahajournals.org/lookup/suppl/doi:10.1161/CIRCRESAHA.116.304393/-/DC1.

Correspondence to Ioakim Spyridopoulos, MD, Institute of Genetic Medicine, Newcastle University Central Parkway, Newcastle Upon Tyne NE1 3BZ, United Kingdom. E-mail ioakim.spyridopoulos@newcastle.ac.uk

© 2014 The Authors. Circulation Research is published on behalf of the American Heart Association, Inc., by Wolters Kluwer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Circulation Research is available at http://circres.ahajournals.org DOI: 10.1161/CIRCRESAHA.116.304393

87
burden of cardiovascular disease in areas of socioeconomic deprivation.²

Previously, only reactivation of cytomegalovirus in immunocompromised hosts was thought to be clinically relevant. However, a growing body of evidence now suggests an important role for cytomegalovirus during aging.³ Cytomegalovirus seropositivity has been estimated to shorten median life expectancy by 4 years in patients aged >65 because of a higher risk of cardiovascular death.¹ Patients with CHD are known to have shorter telomere length (TL) in their peripheral blood leukocytes compared with age-matched healthy adults.⁴,⁵ We have previously shown in patients with chronic myocardial infarction (MI) that the TL of CD8⁺ T cells is shorter than that of all other myeloid and lymphoid leukocyte populations, and in comparison with age-matched seropositive healthy individuals without previous MI.⁶ CD8⁺ T-cell responses in elderly cytomegalovirus-seropositive patients are further characterized by an accumulation of replicatively senescent dysfunctional T cells, also with short TL.⁶ The inverse correlation of telomere shortening in CD8⁺ T cells with left ventricular function additionally suggests a link between a history of MI and immunosenescence.⁵ The aim of this study was to investigate the effect of acute myocardial infarction (AMI) on immunosenescence and cytomegalovirus-specific immunity.

**Methods**

Please see the Online Data Supplement for further details.

**Study Population**

**Cohort A**

A time-course study was performed in 34 patients with ST-segment elevation myocardial infarction (STEMI; mean age, 59.9±11.1 years) who were treated by primary percutaneous coronary intervention (PPCI; Table 1). Blood samples were taken before reperfusion and at 15, 30, and 90 minutes and 24 hours after reperfusion. Additional dextramer substudies were undertaken at 3 months post-MI in 8 cytomegalovirus-seropositive patients.

**Cohort B**

Fifty-four male patients with angiographically confirmed CHD were included in the main study population. Of these, 28 patients had acute STEMI (AMI; mean age, 56±5.8 years) and 26 were stable patients with previously treated STEMI (chronic MI; ≥3 months post-MI; mean age, 61±6 years) and were analyzed 24 hours after

### Table 1. Baseline Characteristics of Cytomegalovirus Subgroups (Cohort A: Time-Course Reperfusion Substudy)

<table>
<thead>
<tr>
<th>AMI (n=34)</th>
<th>Cytomegalovirus Negative</th>
<th>Cytomegalovirus Positive</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>15</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>Age, median (range)</td>
<td>55 (48; 68)</td>
<td>66.0 (58; 72)</td>
<td>0.06</td>
</tr>
<tr>
<td>Sex, male/female</td>
<td>13/2</td>
<td>10/9</td>
<td>0.06</td>
</tr>
<tr>
<td>Previous MI, %</td>
<td>0</td>
<td>0</td>
<td>1.0</td>
</tr>
<tr>
<td>Ejection fraction, %</td>
<td>53 (48; 66)</td>
<td>54 (43; 61)</td>
<td>0.54</td>
</tr>
<tr>
<td>No. of vessel-disease, 1/2/3</td>
<td>15/0/0</td>
<td>17/2/0</td>
<td>0.49</td>
</tr>
<tr>
<td>Serum creatinine, μmol/L</td>
<td>81 (69; 95)</td>
<td>75 (63; 88)</td>
<td>0.31</td>
</tr>
<tr>
<td>HDL cholesterol, mmol/L</td>
<td>1.2 (1.1; 1.4)</td>
<td>1.2 (1.0; 1.4)</td>
<td>0.94</td>
</tr>
<tr>
<td>LDL cholesterol, mmol/L</td>
<td>4.1 (3.1; 5.0)</td>
<td>3.6 (3.2; 4.7)</td>
<td>0.57</td>
</tr>
<tr>
<td>Triglycerides, mmol/L</td>
<td>1.9 (0.9; 2.7)</td>
<td>1.3 (0.8; 2.2)</td>
<td>0.39</td>
</tr>
<tr>
<td>BMI</td>
<td>26 (23; 29)</td>
<td>25 (23; 28)</td>
<td>0.99</td>
</tr>
<tr>
<td>Diabetes mellitus, %</td>
<td>0</td>
<td>5.3</td>
<td>1.0</td>
</tr>
<tr>
<td>Hypertension, %</td>
<td>26.7</td>
<td>36.8</td>
<td>0.72</td>
</tr>
<tr>
<td>Active smokers, %</td>
<td>53.3</td>
<td>52.6</td>
<td>1.0</td>
</tr>
<tr>
<td>Statin treatment, %</td>
<td>20</td>
<td>21.1</td>
<td>1.0</td>
</tr>
<tr>
<td>Initial troponin T, ng/L</td>
<td>40 (17; 132)</td>
<td>61 (33; 141)</td>
<td>0.35</td>
</tr>
<tr>
<td>Peak troponin T, ng/L</td>
<td>4371 (2102; 6200)</td>
<td>4395 (1933; 8408)</td>
<td>0.9</td>
</tr>
<tr>
<td>Onset-to-balloon time, min</td>
<td>135 (112; 219)</td>
<td>164 (114; 211)</td>
<td>0.63</td>
</tr>
<tr>
<td>Door-to-balloon time, min</td>
<td>24 (17; 28)</td>
<td>22 (18; 34)</td>
<td>0.82</td>
</tr>
</tbody>
</table>

All indicated P values (control vs CHD and cytomegalovirus positive vs cytomegalovirus negative) were calculated by nonparametric t test or χ² and Fisher exact test. AMI indicates acute myocardial infarction; BMI, body mass index; CHD, coronary heart disease; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; and MI, myocardial infarction.
PPCI or routine control coronary angiography, respectively (Table 2). Eighteen healthy male volunteers were enrolled as controls (mean age, 53.5 ± 5.8 years).

For both the study populations, none of the patients were knowingly affected by neoplastic, autoimmune, or chronic infectious disease. All subjects with recent infections were also excluded. The study protocol was approved by the institutional ethical committee of Newcastle University (REC 12/NE/0322, cohort A, and REC 09/H0905/50, cohort B). Written informed consent was obtained from all patients and healthy volunteers.

**Blood Collection**
Up to 80 mL of peripheral blood was obtained by venopuncture. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation, cryopreserved, and stored at −80°C as previously described.7

**Enumeration of Peripheral Blood Leukocyte Subsets**
Absolute counts of peripheral blood leukocyte subpopulations were determined using 5-color BD TruCount-based flow cytometry assay as described previously.7

**Determination of Donor Cytomegalovirus Serostatus**
Cytomegalovirus status was determined by enzyme-linked immunosorbent assay (CMV IgG Enzyme Immunoassay Kit; GenWay Biotech, San Diego, CA). Cytomegalovirus IgG concentration was measured in stored (−80°C) serum. Cytomegalovirus seropositivity was defined as an IgG Index of >1, as per manufacturer’s instructions.

**Eleven-Color Flow Cytometry**
For Cohort B, high-throughput 11-color flow cytometry assays were performed as previously described.7 CD8+ T-cell subset counts were calculated as total cells multiplied by percent cells within the subset gate. Gating strategy for 11-color flow cytometry is shown in Online Figure I.

**Hierarchical Cluster Analysis of Flow Cytometry Data**
After data acquisition, files were exported from FACSDiva software and saved as fcs version 3.0 files. The analyzed parameters were 11-color channels (killer cell lectin-like receptor subfamily G member 1 [KLRG1], CD3, CD28, CCR7, CD45RA, CD57, CD27, CD4, CD8, programmed cell death-1 [PD-1], and Aqua Dye) and 3 to 4 parameters based on forward and side scatters (FS-A, SS-A, SS-H, and SS-W). The raw or viable CD3+CD8+ T-cell pregated data were extracted from fcs files and imported into R environment, where all subsequent analysis was performed. Compensation matrix (as present in fcs files) was applied to the data followed by biexponential-like transformation and normalization (z score). Hierarchical cluster analysis (HCA) was then performed using our own previously described algorithm.8 Representative HCA graphical output of the gated viable CD8+ T cells and the heatmaps/dendrograms from all analyzed patients and healthy controls are shown in Online Figures II and III, respectively.

**Dextramer Staining**
Cytomegalovirus-specific T cells were detected in PBMC samples using a Dextramer CMV Kit (Immudex, Denmark). Patient human
leukocyte antigen (HLA) typing was performed by National Health Service Blood and Transplant, Newcastle. Each allele matching the HLA-type of the patient was analyzed separately. Cells were assessed by multiparametric flow cytometry (BD FACS Canto II).

**Seven-Color Flow Sorting of CD8+ T Cells**
Cell sorting was performed on a BD FACS Aria-II cell sorter. Viable CD8+ T-cell subsets were directly sorted and aliquots spun down and dry stored at −80ºC until DNA isolation.

**DNA Isolation and TL Real-Time Polymerase Chain Reaction Assay**
DNA was extracted from sorted CD8+ T cells using a QIAamp DNA Mini Kit (Qiagen Ltd, Crawley, United Kingdom). TL was measured by quantitative real-time polymerase chain reaction with modifications as described previously.9

**Enzyme-Linked–Immunospot Analysis of CD8-Cytomegalovirus–Specific Antigens**
PBMCs were isolated and cryopreserved as for dextramer staining. Enzyme-linked–immunospot analysis was carried out as previously described.10

**IL-7, IL-15, and Interferon-γ ELISA**
Serum IL-7 and IL-15 concentration was determined using MSD 96 Multiarray human IL-7, IL-15, and interferon-γ assays on an SECTOR Imager instrument (Meso Scale Discovery) according to manufacturers’ protocol.

**Th1, Th2, and Th17 Response**
Th1, Th2, and Th17 T-cell responses were assessed by measuring the frequencies of interferon-γ, IL-5, and IL-17–secreting cells, respectively, using enzyme-linked–immunospot assays.

**Proliferation of CD8+ T cells (Ki-67)**
Intracellular Ki-67 T-cell staining was performed on whole-blood samples before (0 minutes), at 90 minutes, and 24 hours after reperfusion. Samples were analyzed by flow cytometry (BD FACS Canto II).

**T-Cell Apoptosis Studies**
For spontaneous apoptosis experiments, PBMCs obtained from STEMI patients before PPCI were incubated in 96-well plates (2×10^6 cells per well) for 16 hours at 37ºC. Cells were washed and stained with anti-CD8 and anti-PD-1 monoclonal antibodies, followed by staining with Annexin V and 7-AAD. For PD-1 blocking experiments, PBMCs were cultured in 24-well culture plates (10^6 cells per well). Cells were stimulated with anti-CD3 monoclonal antibody (Mabtech)

---

**Figure 1.** Myocardial ischemia/reperfusion triggers acute depletion of circulating CD8+ effector memory cells in cytomegalovirus (CMV)-seropositive patients. A, Peripheral blood mononuclear cells (PBMCs) from CMV-seropositive patients with acute myocardial infarction (MI) displayed significantly higher T-helper type-1 (Th1) response (interferon [IFN]-γ enzyme-linked–immunospot assay after PHA stimulation) than PBMCs from CMV-seronegative MI patients already before primary percutaneous coronary intervention (PPCI; Th2 response [IL-5], Th17 response [IL-17]). B, CMV-seropositive MI patients showed increased serum levels of IFN-γ after reperfusion (intraindividual time course from n=15 patients). C and D, Magnitude of Th1 response depends on total ischemic time (onset-to-balloon) in CMV-seronegative MI patients. E, Absolute numbers of leukocyte populations before reperfusion. F, Absolute changes in circulating CD8+ T-cell subpopulations during the first 30 minutes of reperfusion. G, Loss of CD8+ TEMRA cells 24 hours postmyocardial infarction (acute myocardial infarction), compared with healthy controls and patients with chronic MI (Cohort B). H, Increase in proliferating CD8+ T cells 24 hours postreperfusion, as quantified by intracellular staining for Ki-67 and flow cytometry. All bars are mean±SEM. *P<0.05; **P<0.01. ns indicates not significant.
Table 3. Leukocyte Characteristics of Cohort B

<table>
<thead>
<tr>
<th></th>
<th>Healthy Controls</th>
<th>AMI (24 hours)</th>
<th>Chronic MI</th>
<th>P Value 1-Way ANOVA</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>18</td>
<td>28</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>Total leukocyte count, cells/μL</td>
<td>6645±462</td>
<td>12533±757</td>
<td>8312±401</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Total granulocyte count, cells/μL</td>
<td>3732±301</td>
<td>9088±659</td>
<td>5692±280</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Total monocyte count, cells/μL</td>
<td>474±45</td>
<td>874±62</td>
<td>610±48</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Total lymphocyte count, cells/μL</td>
<td>2302±219</td>
<td>2298±167</td>
<td>1885±124</td>
<td>0.13</td>
</tr>
<tr>
<td>Total CD4+ T cells, cells/μL</td>
<td>970±78</td>
<td>1077±92</td>
<td>890±64</td>
<td>0.24</td>
</tr>
<tr>
<td>Total CD8+ T cells, cells/μL</td>
<td>609±95</td>
<td>458±45</td>
<td>507±60</td>
<td>0.27</td>
</tr>
<tr>
<td>CD4/CD8 ratio</td>
<td>1.89±0.15</td>
<td>3.06±0.48</td>
<td>2.38±0.30</td>
<td>0.11</td>
</tr>
<tr>
<td>CD8+ NAIVE count, cells/μL</td>
<td>127±21</td>
<td>82±11</td>
<td>108±14</td>
<td>0.12</td>
</tr>
<tr>
<td>CD8+ EM count, cells/μL</td>
<td>24±6</td>
<td>75±14</td>
<td>28±4</td>
<td>0.0007</td>
</tr>
<tr>
<td>CD8+ CM count, cells/μL</td>
<td>191±33</td>
<td>172±18</td>
<td>139±18</td>
<td>0.27</td>
</tr>
<tr>
<td>CD8+ TEM count, cells/μL</td>
<td>243±59</td>
<td>108±15</td>
<td>215±41</td>
<td>0.03</td>
</tr>
</tbody>
</table>

AMI indicates acute myocardial infarction; and MI, myocardial infarction.

at 5 μg/mL alone or in the presence of 10 μg/mL of blocking anti-CD-1 monoclonal antibody (eBioscience), for 1 or 4 days. Cells were washed and stained with annexin-V, anti-CD3-FITC, and propidium iodide. PBMCs were analyzed using a BD FACSCanto II cytometer.

Statistical Analysis

Data are reported as mean±SE. Comparison of 2 groups was performed using either the Mann–Whitney U test or an unpaired t test, if normal probability–probability plots demonstrated approximate normality. Comparison of 3 means was performed by ANOVA, followed by Tukeys’ post hoc test. Wilcoxon and Friedman tests were used to compare the means of 2 or 3 matched groups, respectively. Correlation analyses were performed with the use of linear regression and Spearman rank coefficient. P<0.05 was considered statistically significant. All statistical tests were performed using GraphPad Prism version 6 for Macintosh (www.graphpad.com).

Results

Myocardial Ischemia/Reperfusion Causes Acute Depletion of CD8 Effector Memory Cells

Seropositive patients displayed a significantly stronger T-helper type-1 (Th1) response (P=0.0072 versus cytomegalovirus-seronegative patients; Figure 1A) immediately before reperfusion. Subsequently, we detected a significant increase in systemic levels of interferon-γ, the signature Th1 cytokine, in cytomegalovirus-seropositive patients after reperfusion (P<0.01 versus seronegative patients at 30 minutes post-PPCI; Figure 1B). The magnitude of Th1 response correlated with total ischemic time in cytomegalovirus-seronegative patients (r=0.71; P=0.0006; Figure 1C–D). In contrast, Th1 response in cytomegalovirus-seropositive patients was higher and did not correlate with ischemic time (r=0.03; P=0.47; Figure 1C–D).

Quantification of blood leukocyte subsets before reperfusion revealed significantly increased concentrations only of cytotoxic CD8+ T cells in cytomegalovirus-seropositive patients (median, 470 versus 272/μL; P=0.026; Figure 1E). Therefore, we focused on the CD8+ T-cell compartment for more detailed study.

The 4 main subsets of circulating human CD8+ T cells (naive CD45RA−CCR7+, central memory (Tcm) CD45RA+CCR7−, effector memory (Tem) CD45RA−CCR7−, and CD45RA+ effector memory (Temra) CD45RA+CCR7−) were sequentially analyzed in STEMI patients after PPCI. Only CD8+ effector memory (Tem and Temra) cell concentration fell (~47 and ~135 cells/μL, respectively) during the initial 30 minutes after reperfusion. When taking cytomegalovirus status and absolute cell concentrations into account, cytomegalovirus-seropositive patients had a 3-fold greater drop in Temra cell concentration than cytomegalovirus-seronegative patients (~192 versus ~63 cells/μL; P=0.008; Figure 1F). Other T-cell subsets did not differ. At 24 hours postinfarction, absolute cell numbers of CD8+ Tem, but not Temra, had fully recovered (Tables 2 and 3). The percentage of CD8+ Temra cells 24 hours postinfarction was significantly lower in acute STEMI patients compared with healthy controls or patients with chronic MI. However, Temra cells were reduced in cytomegalovirus-seropositive AMI patients only and not in cytomegalovirus-seronegative patients (27% versus 40%; P<0.05; Figure 1G). To investigate whether homeostatic proliferation might contribute to the recovery in Temra cells, we quantified IL-7 and IL-15 after reperfusion. Although IL-7 serum levels did not change significantly over time, IL-15 increased from 0.9 to 1.7 pg/mL after 24 hours (P<0.001; data not shown). As expected, proliferating Ki67+ CD8 T cells increased from 3 to 12 cells/μL PB between 90 minutes and 24 hours (P=0.0029; Figure 1H).

It has been shown previously that primary CMV infection (as measured by seroconversion) may occur lifelong and the rate of seroconversion increases with age, with a peak at the age of 30 to 35 years.11 The time point of primary infection determines the duration of virus persistence and exposition to viral antigens, which may largely influence the currently measured immune parameters. To address this question, we performed additional analyses of the CD8 T-cell subset changes after reperfusion studying a larger group of cytomegalovirus-seropositive patients with acute STEMI undergoing PPCI. Patients were divided into 2 groups, such as ≥55 years (young, n=12) and >55 years (old, n=25). Interestingly, although there was no difference in infarct size between groups (reflected by
peak troponin T serum levels after infarction), younger patients (≤55 years of age) demonstrated a more pronounced loss of senescent CD8+ TEMRA cells (delta %CD8+CD27− TEMRA 0–24 hours: −35% versus −0.5%; \( P = 0.04 \); Online Figure IV). In fact, CD8+CD27− TEMRA cells seemed reconstituted in older patients after 24 hours. There was no significant effect of diabetes mellitus on acute changes in the T-cell compartment, as shown in Online Figures V and VI.

Cytomegalovirus-Specific CD8+ TEMRA Cells are Persistently Lost After Myocardial Ischemia/Reperfusion

To phenotype the CD8+ T-cell memory subset that was depleted 24 hours after reperfusion, we used a computerized algorithm for 13-parameter polychromatic analysis, followed by HCA in 10 cytomegalovirus-seropositive patients and 10 cytomegalovirus-seropositive controls (Figure 2A and 2B). The algorithm identified 3 CD8+ clusters (naïve, TEM, and senescent TEMRA cells) that were present in all 20 samples (Figure 2C). Cluster 9, which contained terminally differentiated TEMRA cells was contracted in patients 24 hours post-MI compared with controls (median, 8% versus 23%; \( P = 0.0021 \); Figure 2D). We then compared the frequencies of cells resembling the phenotype of cluster 9 (CD3+CD4+CD27−CD28−CD57+KLRG1+) in cytomegalovirus-seropositive and cytomegalovirus-seronegative patients, to determine whether this cluster harbored mainly cytomegalovirus-specific cells. We found that CD8+ TEMRA cells of this phenotype were increased ≤90 cells/μL in cytomegalovirus-positive CHD patients after MI, compared with 6 cells/μL in cytomegalovirus-negative patients (\( P < 0.0001 \); Figure 2E). Using conventional gating strategies, we then investigated whether it was only specific subsets of CD8+ TEMRA cells that were lost after MI. Surprisingly, CD27+CD28+ TEMRA cells were unaffected, while CD27−CD28− TEMRA cells showed the largest decrease compared with controls (11.6% versus 21.9%; \( P = 0.009 \); Figure 3A). To then prove the loss of cytomegalovirus–specific memory T cells, we used HLA class I cytomegalovirus–specific dextramers (Figure 3B). The percentage of cytomegalovirus–specific CD8+ T cells that could be detected with individual HLA-specific dextramers ranged from 0.2% to 18% between patients and HLA-specific epitopes (Figure 3C). Furthermore, compared with their relative proportion before reperfusion, we saw a significant decline in cytomegalovirus–specific CD8 T cells to 24% at 90 minutes, 53% at 24 hours, and 54% at 3 months (Figure 3B and 3D). In addition, we found that the number of cytomegalovirus–specific CD8+ T cells did not correlate with the magnitude of memory cells reacting to cytomegalovirus antigen in the enzyme-linked–immunosassay. This was illustrated by an inverse relationship between dextramer-positive cells and the proportion of functional cells among them \( (r=−0.79; \ P = 0.006 \); Figure 3E).

PD-1+ TEMRA Cells Become Depleted During AMI

Attrition of virus-specific CD8+ T cells has been linked to PD-1 (programmed death-1), which can be upregulated on the surface of memory T cells on activation. We, therefore, determined if PD-1 was responsible for the selective loss of CD8+ TEMRA cells in STEMI patients undergoing PPCI. Co-staining of CD8 T-cell populations with CD69 showed that...
10% of T\textsubscript{EMRA} cells were activated before reperfusion, as opposed to only 2% of naive cells (P=0.016; Figure 4A). PD-1\textsuperscript{+} T\textsubscript{EMRA} cells were specifically depleted during the first 90 minutes of reperfusion (P<0.01; Figure 4B). Twenty-four hours after reperfusion, cytomegalovirus-seropositive patients had a smaller proportion of PD-1\textsuperscript{+} cells among their CD8\textsuperscript{+} T\textsubscript{EMRA} cells than cytomegalovirus-seronegative patients (23% versus 34%; P=0.04; Figure 4C). Accordingly, the percentage of PD-1\textsuperscript{+} cells before PPCI strongly correlated with the relative loss of circulating CD8\textsuperscript{+} T cells within 24 hours after reperfusion (r=−0.8; P=0.0002; Figure 4D).

PD-1 expression has been associated with a higher susceptibility of CD8 T cells to apoptosis ex vivo.\textsuperscript{12} We, therefore, sought to investigate the role of PD-1 in spontaneous and induced apoptosis of T cells from STEMI patients. Our results show that apoptosis sensitivity depends on PD-1–expression level on CD8\textsuperscript{+} T cells (Figure 4E). Accordingly, PD-1\textsuperscript{dim} and PD-1\textsuperscript{high} cells displayed significantly higher susceptibility to spontaneous apoptosis ex vivo, when compared with PD-1\textsuperscript{neg} cells (P<0.05 for % early apoptosis PD-1\textsuperscript{dim} versus PD-1\textsuperscript{neg}, and P=0.001 for % late apoptosis PD-1\textsuperscript{high} versus PD-1\textsuperscript{neg} CD8\textsuperscript{+} T cells, accordingly; Figure 4F–4H). Moreover, ex vivo PD-1 blockage significantly reduced the rate of CD3-induced apoptosis in T cells from cytomegalovirus-positive patients (32% versus 16%; P=0.03; Figure 4I). We further tested PD-1 expression levels on cytomegalovirus-specific CD8\textsuperscript{+} T cells (Figure 4J). Here, cytomegalovirus dextramer–positive cells showed a higher mean percentage of PD-1\textsuperscript{med/high} subsets than dextramer-negative CD8\textsuperscript{+} T cells (P=0.04; Figure 4K). STEMI patients with a higher percentage of PD-1\textsuperscript{+} cytomegalovirus-specific cells before reperfusion displayed a significantly higher loss of CD8\textsuperscript{+} T\textsubscript{EMRA} cells within 24 hours post-PPCI (P=0.02; Figure 4L).

Although selective loss of PD-1\textsuperscript{+} cells during reperfusion (via apoptosis) might in part explain PD-1 deficiency in CD8 memory compartments, it might also indicate a limited ability of cytomegalovirus-seropositive patients to suppress T-cell responses in a PD-1–dependent manner. We, therefore, determined the immunophenotypic characteristics of PD-1\textsuperscript{neg} and PD-1\textsuperscript{neg} CD8\textsuperscript{+} effector memory cell subsets (Figure 5A). Here, we observed that PD-1\textsuperscript{neg} T\textsubscript{EMRA} cells from cytomegalovirus-seropositive patients showed no significant difference in the expression of differentiation and senescence markers CD27, CD28, CD57, and KLRG1 when compared with cytomegalovirus-seronegative patients (Figure 5B).
markers at low level, all TEMRA cells and the majority of TEM cells expressed high levels of KLRG1 (Figure 6A). However, CD57, which also reflects the proliferative history of cells, was specifically upregulated in TEM cells of patients 24 hours after myocardial infarction. In TEMRA cells, KLRG1 expression was highest in patients with chronic MI (Figure 6A).

To quantify mean telomere length in different CD8+ subsets, we used 7-color flow cytometric cell sorting, followed by TL real-time polymerase chain reaction (Figure 6B). TL of CD8+ T cells in cytomegalovirus-seropositive individuals declined from healthy controls to patients with AMI and chronic MI (3397 versus 2814 versus 2225 bp; \(P<0.001\); Figure 6C). This was mainly attributed to chronic patients with previously large heart attacks, complicated by congestive heart failure (Figure 6C). Finally, we measured TL of effector memory populations (CD8+ TEM and TEMRA cells) in relation to the same patients' naive cell TL, the latter serving as an intrapatiental baseline for the longest telomeres of any CD8 subset. TL was \(\approx 1000\) to 1400 bp shorter in TEM cells between controls and chronic MI patients (\(P=0.21\)), but significantly shorter in TEMRA cells from patients with chronic MI (2000 versus 600 bp; \(P=0.0015\); Figure 6D).

Discussion

In this study, we demonstrate the depletion of circulating CD8 memory T cells after AMI and reperfusion. These quantitative changes seem to be reversible for all but terminally differentiated memory (TEMRA) cells in cytomegalovirus-seropositive patients. Our results suggest that PD-1, the programmed death protein-1, might be involved in the persistent loss of TEMRA cells in cytomegalovirus-seropositive patients. We have used 3 different methods to confirm the specific depletion of TEMRA cells, which have previously been shown to harbor the majority of cytomegalovirus-specific cytotoxic cells.13 Polychromatic flow cytometry identified a reduction in CD27−CD28− double negative CD8+ TEM cells during AMI, and HCA yielded a selective depletion of CD27−CD28−CD57+KLRG1+ CD8+ T cells. Finally, by using HLA type I-specific dextramers, we found a reduction in cytomegalovirus-specific cytotoxic T cells, which persisted between 24 hours and 3 months after MI.
Although age seemed to have an effect on T-cell recovery by 24 hours (Online Figure IV), it is important to emphasize that the relative changes observed within 24 hours after reperfusion might indeed not reflect the cumulative effects of ischemia/reperfusion. This is most probably because lymphocyte counts at the time point of PPCI cannot be considered as a true baseline after several hours of already ongoing ischemia. Therefore, our additional cross-sectional analysis (AMI versus chronic MI) is a potentially more objective visualization of the CD8+ TEMRA contraction and absolute T-cell losses in the course of AMI and reperfusion.

The implications of these findings are 2-fold: First, the loss of cytomegalovirus-specific memory cells may diminish the antiviral T-cell potential, enhancing latent reactivation of the virus and sustaining low-grade chronic inflammation. Second, cytotoxic TEMRA cells could enhance myocardial necrosis or delay infarct healing through direct migration into peri-infarct tissue.14

Acute Stress–Induced Redistribution of T-Lymphocytes
A short-term decrease in circulating CD8 T-lymphocytes may reflect trafficking of cells out of the bloodstream and into different target organs, including the spleen, lung, lymph nodes, or the site of inflammation.15 There are 2 major signaling pathways that have been shown to be involved into T-lymphocyte migration and egress. First, migration of T cells is influenced by the sphingosine-1 phosphate pathway.16 Lympocyte egress from lymph nodes requires the S1P1 receptor, and the transmembrane C-type lectin CD69 inhibits S1P1 chemotactic function and leads to downmodulation of S1P1.17 Second, epinephrine has been shown to cause acute demargination of T-lymphocytes by suppressing adhesive fractalkine signaling.18 The receptor for fractalkine, CX3CR1, is mainly expressed in cytoxic CCR7- or CD62L-negative T-lymphocytes, coinciding with the egressing cell populations in our study.18 In our opinion, fractalkine signaling could be a promising target to investigate the role of CD8 T cells in ischemia/reperfusion in the future.

Role of PD-1 in Persistent Loss of Cytomegalovirus-Specific T Cells
PD-1 is an inhibitory surface receptor, which is upregulated on memory T cells on activation.19 PD-1 is known to inhibit CD8+ T-cell effector functions by dampening T-cell responsiveness to antigenic stimulation.20 PD-1 expression has also been linked to a proapoptotic phenotype of CD8+ T cells.21 Our data show that in CD8+ T cells from patients with acute STEMI spontaneous apoptosis occurs mainly in cells expressing high levels of PD-1. In addition, blocking PD-1 could reduce the ratio of induced CD8+ T-cell apoptosis ex vivo. We, therefore, questioned whether PD-1 expression on effector memory T cells could be associated with the acute inflammatory response and CD8+ T-cell loss in STEMI patients undergoing PPCI. We found that 24 hours after reperfusion, cytomegalovirus-seropositive patients displayed significantly lower proportions of PD-1+ CD8+ TEMRA subsets in comparison with cytomegalovirus-seronegative patients. Furthermore, CD8+ TEMRA cells showed the highest amount of activation, as evidenced by CD69 staining, and the PD-1+ subpopulation were specifically depleted during the first 30 minutes of reperfusion. This loss was not secondary to increased senescence, as documented by similar CD27, CD28, KLRC-1, and CD57 expression in PD-1−positive versus PD-1−negative subsets.22 Altogether, these findings are highly suggestive of a specific role of PD-1 in the permanent loss of TEMRA and cytomegalovirus-specific cells during MI. Indeed, Zhang et al23 have recently demonstrated that upregulation of PD-1 during acute viral infection is involved in the attrition of cytomegalovirus-specific cells. Accordingly, PD-1 has been shown in mouse models to limit T-cell responses in cardiomyocytes and in the arterial wall, thereby protecting from atherosclerosis and myocarditis.24,25

Coronary Artery Disease and Immunosenescence
There is an increasing evidence for continuous immune activation in CHD patients, characterized by accumulation of immunocompetent cells in the arterial lesion and elevated levels of inflammatory markers in the circulation.26 A cross-sectional
study in >7700 participants found that cytomegalovirus seropositivity was significantly associated with a history of cardiovascular disease. A further longitudinal study has shown a significant increase in CHD-related mortality in cytomegalovirus positive, but otherwise healthy individuals over the course of 17 years. This translated into shortening of lifespan by ≈3.7 years. We have also found a significant increase in CHD among cytomegalovirus-seropositive participants in the Newcastle 85+ study (Spyridopoulos et al, manuscript in preparation), in which we investigated 751 participants of the same age group (85 years). Interestingly, the presence of senescent CD4 and CD8 memory T cells was an independent predictor of mortality even in this age group. We have previously demonstrated that cytomegalovirus-seropositive patients with chronic myocardial infarction have increased telomere shortening in their CD8 T-cell compartment when compared with cytomegalovirus-seropositive healthy controls, indicating differences in the pathobiology of cytomegalovirus-driven immunosenescence in patients with CHD. This effect was more pronounced in patients with more extensive infarction and more severely impaired left ventricular function. This could be explained by ≥3 reasons: (1) genetic differences, leading to better control of the virus in patients without CHD, such as is seen in offspring from longevity families, (2) underlying inflammation as present in atherosclerosis, driving latent cytomegalovirus infection, and (3) changes in the CD8 compartment that are related to AMI, particularly in younger cytomegalovirus-seropositive MI patients, as seen in our present study. Another interesting aspect in our analysis was that the proportion of functional cytomegalovirus-specific cells, as indicated by spot forming cells in response to cytomegalovirus antigen, declined sharply with the total number of dextramer-positive cytomegalovirus-specific cells. This suggests that patients with a large cytomegalovirus-specific T-cell repertoire actually still contain relatively fewer cells that can control the latent infection. It is, therefore, conceivable that
the lack of effective virus control in cytomegalovirus-seropositive patients instigates further low-grade inflammation in the arterial wall, accelerating atherosclerosis.28

Conclusions
Our results suggest that the temporary loss of cytomegalovirus-specific cells in patients after MI diminishes the potential for the host to contain latent cytomegalovirus-infection, leading to homeostatic proliferation of T cells to replenish effector memory subsets.29 This proposed mechanism could explain accelerated CD8 T-cell immunosenescence in cytomegalovirus-seropositive patients with MI, as well as progression of atherosclerosis. In light of an aging population and cytomegalovirus prevalence of up to 90% in the elderly, future strategies to delay or reverse T-cell immunosenescence, such as early vaccination against cytomegalovirus or pharmacological interventions aimed at direct deenergising memory T cells,29 but also adjuvant, anti-inflammatory, age-decelerating treatment options, including statins might prove beneficial for patient outcome in older patients.33,34

Limitations
The main limitation of our study is the lack of longitudinal data (beyond 4 months) in the same patient with MI. Furthermore, because of relative low number of patients within the particular study groups, only limited subanalyses of the effect of diabetes mellitus and age on the observed acute and chronic changes within the T-cell compartment after reperfusion could be performed. Finally, the view of our observations with respect to potential therapeutic interventions in cytomegalovirus-seropositive CHD patients remains uncertain. Future prospective studies are needed to prove the value of T-cell senescence as a predictor of adverse outcome in these patients and identify potential cellular targets for immunomodulatory interventions.

Sources of Funding
This work was supported by a British Heart Foundation award to IS (FS/12/31/29533; http://www.bhf.org.uk/), National Institute for Health Research Newcastle Biomedical Research Centre (IS), and the Newcastle Healthcare Charity (http://www.newcastle-hospitals.org.uk/donations_charity-matters_about-us.aspx, I.S.). K.F. is supported by MH CZ-DRO, UH Motol, Prague, Czech Republic 64203.

Disclosures
None.

References
Chronic infection with cytomegalovirus affects the majority of the population in Western countries and is thought to instigate chronic low-level inflammation. Cytomegalovirus infection is also associated with an increase in the incidence of coronary heart disease. We have found that acute myocardial infarction with subsequent reperfusion of the infarcted tissue by stent insertion triggers a temporary decrease of all CD8 T-lymphocytes as well as a more persistent loss of cytomegalovirus-specific memory lymphocytes, most probably through apoptotic cell death via the programmed cell death-1 receptor. This leads to reactivation of the adaptive immune system with accelerated proliferation and aging of memory lymphocytes, promoting a vicious circle where aged immune cells can lead to even further inflammation and, therefore, faster progression of underlying atherosclerosis. These findings highlight the need for immune-specific interventions in cytomegalovirus-seropositive patients with acute myocardial infarction, such as anti-inflammatory drugs that can reverse aging of memory lymphocytes.
Myocardial Ischemia and Reperfusion Leads to Transient CD8 Immune Deficiency and Accelerated Immunosenescence in CMV-Seropositive Patients

Circ Res. 2015;116:87-98; originally published online November 10, 2014;
doi: 10.1161/CIRCRESAHA.116.304393
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/116/1/87
Free via Open Access

Data Supplement (unedited) at: http://circres.ahajournals.org/content/suppl/2014/11/10/CIRCRESAHA.116.304393.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/
SUPPLEMENTAL MATERIAL

DETAILED METHODS

Blood Collection
Up to 20 ml (Cohort A) or 80 ml (Cohort B) of peripheral blood (PB) was obtained by venopuncture. Absolute leukocyte counts were determined and blood samples maintained at room temperature (RT, 18-21°C) until Ficoll gradient processing within 4 hours. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation, cryopreserved and stored at -80°C as previously described. Serum was obtained after centrifugation of blood filled native-serum tubes for 10 minutes at 3600 rpm at 4°C. Serum aliquots of 1 ml were immediately frozen and stored at -80°C for further analysis.

Enumeration of peripheral blood leukocyte subsets
Absolute counts of PB granulocyte, monocyte and lymphocyte subpopulations were determined using a 5-colour BD TruCount flow cytometry assay (BD Biosciences, San Jose, CA, USA) as described previously. Briefly, 50µl of freshly drawn peripheral EDTA blood were added into TruCount tube using reverse pipetting and stained with 10 µl CD3/CD8/CD45/CD4 BD Multitest reagent (containing anti-CD3-FITC, anti-CD8-PE, anti-CD45-PerCP, and anti-CD4-APC monoclonal antibodies, Cat. No. 342417, BD Biosciences) and 5 µl of anti-CD14-Pacific Blue (Cat. No. MHCD1428, Invitrogen). Following 20 min incubation at room temperature in the dark, erythrocytes were lysed for 15 minutes with 1500 µl ammonium chloride-based lysing buffer (BD PharmLyse, Cat. No. 555899, BD Biosciences). Data acquisition was performed on BD FACS Canto II flow cytometer (BD Biosciences) using
FACSDiva software (BD Biosciences). Threshold was set on CD45 PerCp channel and 10000 of CD45 positive lymphocytes were counted for the stop gate. Spectral overlap between different channels was calculated automatically by the FACSDiva software after measuring single-colour compensation controls. Optimal compensation was achieved using antibody capture beads (Anti-Mouse Ig κ CompBeads, Cat. No. 552843 BD Biosciences) and the corresponding conjugated antibodies (see below). Data was analyzed using FACS-Diva Software and absolute cell counts per µl PB were calculated according to manufacturer’s protocol.

**Multi-color flow cytometry**

For Cohort B, high-throughput 11-colour flow cytometry (FCS) assays were performed from cryopreserved PBMCs as previously described. PBMC cell suspensions were stained with a cocktail of antibodies against T-cell epitopes comprising directly conjugated anti-CD3-QDot-605 and CD16-PacificBlue (Invitrogen – Life Technologies, Paisley, UK), anti-CD4-AlexaFluor-700, CD8-APC-H7, CD27-APC, CD28-PerCpCy5.5 and CCR7-PE-Cy7 (BD Biosciences, San Jose, CA, USA). Anti-KLRG1-AlexaFluor-488 antibody (clone 13F12) was generated as previously described. For indirect immunofluorescence, purified mouse anti-human-CD57 (BD) and biotin-labeled anti-PD1 (eBioscience, San Diego, CA, USA) were used as primary antibodies. Secondary staining was performed with AlexaFluor-350-labeled Goat-anti-mouse (BD) and Streptavidin-AlexaFluor532 (Invitrogen), respectively. For dead cell exclusion LIVE/DEAD® Fixable Aqua Dead cell dye (Invitrogen) was included in the PBMC staining panel. Samples were measured using a BD LSR II cytometer equipped with 5 lasers using BD FACSDiva acquisition software. PMT voltages and compensation values were as previously described. At least 100,000 viable cell events per sample were acquired. Spectral overlap between different
fluorochromes was calculated automatically by the FACSDiva software (BD) as described previously.\textsuperscript{1} Data were analyzed using R Project (for Hierarchical Cluster Analysis, see below) or FlowJo software (Treestar, Ashland, OR, USA, Version 9.4.1 for Macintosh). Two-dimensional plots (pseudo-color or dot plot) were created using biexponential transformation and sequential gating of CD8\textsuperscript{+} T cells was performed according to the model of T-cell memory differentiation as described by Sallusto and Romero\textsuperscript{3-5} (see Supplementary Figure I). CD8\textsuperscript{+} T-cell subset counts were calculated as total cells multiplied by percent cells within the subset gate.

For Cohort A, 8-colour flow cytometric analysis was performed in whole blood. Briefly, 50\mu l aliquots of blood were stained with a cocktail of the following antibodies: anti-CD3-FITC, CD4-V500, CD8-APC-H7, CD16-PE, CD27-APC, CCR7-PE-Cy7 (all BD), CD45RA-Pacific Blue (Invitrogen) and CD56-PerCP-eFluor710 (eBioscience). The samples were then lysed using Pharmlyse (BD) lysis buffer according to manufacturers instructions, followed by two wash steps in BD Cellwash using BD Lyse/wash Assist machine. Analysis was performed using BD FACS Canto II machine with FACSDiva software (BD), and gating performed using the same model described above.

**Dextramer staining**

CMV-specific T cells were detected in PBMC samples using a Dextramer CMV Kit (Immudex, Denmark). Briefly, this comprised 8 different CMV-specific dextramers conjugated with PE representing 7 different alleles: A*0101, A*0201, A*0301, A*2402, B*0702, B*0801 and B*3501. Patient HLA typing was performed by NHS Blood and Transplant Newcastle. Each allele matching the HLA-type of the patient was analyzed separately. Monoclonal antibodies CD3-FITC, CD27-APC, CD8-APC-
H7 (BD) and CD45RA-PacificBlue (Invitrogen) were used to identify subpopulation phenotypes of CMV-specific cells. Before staining, PBMCs were quickly thawed in a 37°C water bath for 1–2 min. After washing twice with PBS containing 5% fetal calf serum (PBS/5%FBS), pH 7.4, cells were resuspended in PBS/5%FBS. Viable PBMCs were determined by Vi-CELL Cell Viability Analyzer (Beckman Coulter). 1x10^6 cells were resuspended in a total volume of 50 µl PBS/5%FBS and incubated with 10 µl appropriate MHC dextramer in the dark at room temperature. After a 10 minute incubation, appropriate amounts of CD3-FITC, CD27-APC, CD8-APC-H7, CD45RA-PacificBlue monoclonal antibodies were added to the sample and incubated for at least 20 minutes at room temperature. Finally, cells were washed twice with PBS/5%FBS and assessed by multiparametric FCS (BD FACS Canto II).

7-colour flow sorting of CD8^+ T Cells

3x10^7 cryopreserved PBMCs were used for fluorescence-activated cell sorting. Cell aliquots were processed as described previously. Prior to staining, cells were evaluated for size, viability and concentration using the Vi-Cell analyzer. PBMC staining was performed using a pre-titrated antibody mix containing anti-human-CD3-FITC, CD4-PE-Cy7, CD8-APC-H7, CCR7-PE, CD27-APC (BD), CD45RA-PacificBlue and Aqua dead cell dye (Invitrogen). Cell sorting was performed on a BD FACS Aria-II cell sorter equipped with 4 lasers. The sorting conditions were a 70 micron nozzle at 70 psi, using a high purity mask and acquisition speed below 10000 events per second. 3-5x10^5 of viable total CD8^+, as well as 1-3x10^5 of naïve (CCR7^+CD45RA^+CD27^+), T_{EM} (CCR7^−CD45RA^−) and terminally differentiated T_{EMRA} (CCR7^−CD45RA^+CD27^−) CD8^+ T cells were directly sorted and aliquots spun down and dry stored at -80ºC until DNA isolation.
DNA isolation and telomere length RT-PCR assay

DNA was extracted from sorted CD8\(^+\) T cells using a QIAamp DNA Mini Kit (Qiagen Ltd, Crawley, UK). DNA concentration and quality were monitored by agarose gel electrophoresis. Samples were discarded if DNA degradation (smear <20 kb) was visible. Telomere length was measured as the ratio of the starting quantity for telomeres versus the starting quantity for the single copy gene of glyceraldehyde-3-phosphate dehydrogenase (as control) by quantitative real-time polymerase chain reaction (PCR)\(^6\) with modifications as described previously.\(^7\) Measurements were performed in quadruplicate. Three DNA samples with known telomere lengths (3.0, 5.5 and 9.5 kb pairs) were run as internal standards together with each batch of 16 study samples to convert the ratios of starting quality into telomere lengths in base pairs. The intra-assay coefficient of variation for this PCR method was 2.6% and the inter-assay coefficient of variation was 5.1%.

ELISPOT analysis of CD8-CMV specific antigens

PBMCs were isolated and cryopreserved as for dextramer staining. ELISPOT analysis was carried out as previously described.\(^8\) In brief, cells were thawed, washed and resuspended in RPMI-1640 (Sigma-Aldrich, Poole, UK) containing 10% heat-inactivated fetal bovine serum (BioSera, E. Sussex, UK), 100 U/mL penicillin +100 µg/mL streptomycin and 2 mM l-glutamine (Sigma). PBMCs were counted using an automated CasyCounter TT (Roche Innovatis AG, Bielefeld, Germany). PBMCs were plated in duplicate wells at 0.4 million per well on MultiScreen 96-well HPVDF filtration plates (MAIPS4510, Millipore) that had been coated overnight at 4°C with 10 µg/mL of anti-IFN-γ (1-D1K, Mabtech, Nacka, Sweden) and blocked with the supplemented medium described above. Cells were incubated (37°C, 5% CO\(_2\)) for 18 – 20 hours with positive (phytohaemagglutinin 5 µg/mL, Sigma) or negative
(supplemented medium) controls, or peptide pools consisting of up to 20 peptides representing the main epitopes from CMV (final concentration 10 µg/mL/peptide), or a CMV lysate (1 in 100). Plates were developed using anti-IFN-γ-biotin conjugate, streptavidin-ALP (Mabtech) and the addition of chromogenic substrate (BioRad, Hercules, CA, USA). Spots were counted using an ELISPOT reader and associated software (both AutoImmun Diagnostika, Germany). Final counts were expressed as spot-forming cells /million PBMCs after averaging duplicate well counts and subtracting background.

**IL-7, IL-15 and IFN-γ ELISA**

Blood of 15 STEMI patients undergoing PPCI was collected in BD Vacutainer® SST™ Advance Tubes at 5 different time points after reperfusion (pre-, 15m, 30m, 90m, 24h). Samples were centrifuged at 1000g for 10 minutes, and serum aliquoted into CryoTube vials (Fisher Scientific, Loughborough, UK) for storage at -80°C. Serum samples were thawed to measure IL-7 and IL-15 levels using the MSD 96 Multi-array human IL-7, IL-15 and IFN-γ assays on a SECTOR Imager instrument (Meso Scale Discovery, Rockville, MD, USA) according to manufacturers’ protocol.

**Th1, Th2 and Th17 response**

Phytohaemagglutinin (PHA) at 5µg/ml was used to determine total number of T cells secreting IFN-γ, IL-2, IL-5, and IL-17. ELISPOT plates were coated with capture antibodies anti-IFN-γ (Mabtech, Nacka Strand, Sweden), IL-2 (R&D systems, Abingdon, UK), IL-5 (Mabtech) and IL-17 (eBioscience, San Diego, USA). PBMCs were stimulated with PHA for 20 hours in a 37°C/CO2 incubator. The plates were then developed using biotinylated detector antibodies, streptavidin-ALP (Mabtech) and the addition of chromogenic substrate (BioRad, Hercules, CA, USA).
**Proliferation of CD8^+ T cells (Ki-67)**

Patients blood samples were collected in EDTA-containing BD Vacutainer tubes before, at 0 min, 90 min and 24 hours following reperfusion. 100 µl of whole blood per test was stained with CD3-PerCP, CD4-V500, CD8-APC-H7 monoclonal antibodies (mAb) (BD Biosciences), lysed by BD Pharm Lyse solution (1ml per sample), washed twice in PBS and finally resuspended in PBS containing 1% formaldehyde. After fixation, cells were washed twice in PBS and then incubated for 10 minutes with BD FACS Permeabilizing Solution 2 (0.5 ml per sample) followed by two washing steps in PBS containing 5% FBS. To complete intracellular staining, cells were incubated with 20 µl of Ki-67-PE mAb (BD Biosciences) for 30 minutes at room temperature in the dark. After repeated washing, samples were analyzed by flow cytometry (BD FACS Canto II).

**Spontaneous T-cell apoptosis assay**

Cryopreserved PBMCs were thawed, washed and resuspended in RPMI 1640 + Glutamine (Life Technologies) containing: 0.5mM 2-mercaptoethanol (Sigma, M7522), 25mM Hepes Buffer (Gibco, 15630-080), 10% FBS (Life Technologies) and 30 g/ml of pen/strep. The cells were plated at 2x10^5 cells in total volumes of 200µl per well on a 96-well-plate and incubated for 16 hours (37°C, 5% CO₂). Then cells were washed in PBS, counted, resuspended in PBS and stained with anti-CD8-APC-H7 (BD, Catalog Number: 641400) and anti-PD1-APC (BD, Catalog Number 558694) mAbs. Now cells were washed again and resuspended in 1 x Annexin V Binding Buffer (BD, Catalog Number: 556454) followed by staining with Annexin V-FITC (BD, Catalog Number: 556429) and 7-AAD (BD, Catalog Number: 559925). Finally, samples were analysed on a BD FACS Canto II.
Induced T-cell apoptosis assay with PD1-blocking

PBMCs from 6 CMV+ STEMI patients, isolated prior to reperfusion, were cultured in a 24-well culture plate at 10^6 cells per well in complete RPMI. Cells were stimulated with stimulatory anti-CD3 monoclonal antibody (Mabtech) at 5ug/ml alone or in the presence of 10ug/ml of blocking anti-PD-1 monoclonal antibody (eBioscience), for 1 or 4 days. Cells were washed and stained with annexin-V-APC in binding buffer (eBioscience), anti-CD3-FITC, and propidium iodide (PI) and were analysed using a BD FACSCanto II cytometer, and data processed using DIVA. Gating was on the CD3^+ lymphoblasts responding to the stimulus. Annexin-V^+ PI^+ double positive cells indicated the late apoptotic population.
Online Figure I. Example of gating path for 11-colour FCS from cryopreserved PBMCs (healthy control). Following exclusion of dead cells, T cells are divided into naive, central memory, effector memory and T_{EMRA} CD8^+ cells. At the next level, coreceptors CD27 and CD28 are stained. Finally, co-expression of senescence/proliferation markers, KLRG-1, CD57 and PD-1 is shown.
Online Figure II

A. Dendroheatmap. Heatmap has cells as rows and measured parameters as columns with level of parameter colour-coded: red-high, yellow-medium, blue-low, cyan-negative. Three major clusters were selected: 5 (red), 7 (orange) 9 (purple).

B. Conventional scatterplot matrix representation of the main selected CD8 T-cell clusters.

Online Figure II. Example of HCA analysis of the gated viable (Aqua dye-negative) CD8⁺ T cells from a healthy donor sample. A. Dendroheatmap. Heatmap has cells as rows and measured parameters as columns with level of parameter colour-coded: red-high, yellow-medium, blue-low, cyan-negative. Three major clusters were selected: 5 (red), 7 (orange) 9 (purple). B. Conventional scatterplot matrix representation of the main selected CD8 T-cell clusters.
Online Figure III

Representative HCA analysis with dendroheatmaps from 5 healthy control donors and 5 STEMI patients (24 hours following reperfusion). Numbers indicate original donor IDs within the study. Three major ubiquitous clusters (red, orange and purple) were further displayed using higher cutting level (data not shown) and subjected to the inter-group statistical analysis (see main text).
Online Figure IV. Influence of age on the acute changes of CD8 T-cell subsets in CMV-seropositive patients following reperfusion. 

A. Maximum troponin T (representing the extent of MI) in younger (≤55 years) and older (>55 years) patients.

B. Relative changes in CD8 T-cell subsets in younger and older patients within 90 min after reperfusion.

C. Relative changes in CD8 T-cell subsets in younger and older patients within 24 hours after reperfusion.
Online Figure V. Influence of diabetes mellitus on the acute and chronic changes of T-cell subsets in CMV-seropositive patients following reperfusion. Significance level changes following data re-analysis after exclusion of the diabetic patient from the CMV-seropositive group of the Cohort A. **Within dot plots, green dots indicate diabetic patients**
Online Figure VI. Influence of diabetes mellitus on the chronic changes of T-cell subsets in CMV-seropositive patients following reperfusion. Data re-analysis after exclusion of the diabetic patients from the CMV-seropositive and -seronegative groups of the Cohort B. **Within dot plots, green dots indicate diabetic patients**
SUPPLEMENTAL REFERENCES


